Professor Fengmin Lu

Director of the Peking University Infection Disease Research Center，Dual-appointed Professor at the Infectious Diseases Center of Peking University Third Hospital

Contact Information

Email：lu.fengmin@hsc.pku.edu.cn

Research Interests

Research on the pathogenesis of hepatitis B virus (HBV) and related liver diseases, as well as the development of diagnostic markers.

Personal Profile

Currently serves as a member of the Expert Committee on Laboratory Safety of the Ministry of Science and Technology and the Beijing Municipal Government, Chairperson of the Medical Virology Branch of the Beijing Medical Association, and Chief Scientist of the "Sanming Project of Medicine in Shenzhen.Previously served as Secretary of the Hepatology Group for the Implementation Plan of the Major National Science and Technology Project for Infectious Disease Prevention and Control, and as a member of the Basic Medicine Group of the Academic Degrees Committee of the Ministry of Education.

Key contributions

· Proposing the critical role of host gene functions affected by HBV integration in HBV-induced carcinogenesis.

· Updating the definition of occult HBV infection (OBI) and establishing corresponding diagnostic methods.

· Experimentally confirming the existence of HBV RNA virus-like particles, thereby refining the HBV life cycle.

· Identifying serum GP73 as a diagnostic marker for cirrhosis in chronic liver diseases of various etiologies.

· Diagnostic reagents developed based on the above findings have been approved for clinical application.

Research Projects and Achievements

As a principal investigator, he has undertaken more than 20 research projects, including projects under the "National Science and Technology Major Project for Infectious Disease Prevention and Control" during the 11th, 12th, and 13th Five-Year Plans, General Program of the National Natural Science Foundation of China, Major Projects of the Beijing Municipal Science and Technology Commission, as well as projects under the "863 Program" and "973 Program".

As the first completer, he won one Second Prize of the Chinese Medical Science and Technology Award; as a completer, he won two Second Prizes of the National Science and Technology Progress Award.

He has published nearly 200 research papers in domestic and international journals, which have been cited nearly 10,000 times. He has obtained 25 authorized invention patents, 7 of which have been transferred for application.